# Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

> **NCT00325156** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2590 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Poliomyelitis
- Acellular Pertussis
- Haemophilus Influenzae Type b
- Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines

## Interventions

- **BIOLOGICAL:** GSK Biologicals' combined DTPa-IPV/Hib vaccine

## Key facts

- **NCT ID:** NCT00325156
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11-02
- **Primary completion:** 2007-08-23
- **Final completion:** 2007-08-23
- **Target enrollment:** 2590 (ACTUAL)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325156, "Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00325156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*